1.Department of Integrated Traditional Chinese and Western Medicine 2.Dean's Office 3.Department of Clinical Pharmacology,General Hospital of Central Theatre Command of the Chinese People's Liberation Army,Wuhan 430070,China
Objective To investigate the clinical efficacy and mechanism of Qingfei Touxie Fuzheng recipe in the treatment of coronavirus disease 2019 (COVID-19). Methods One hundred COVID-19 patients were randomly divided into the treatment group (n=51) and the control group (n=49). According to the Diagnosis and Treatment Plan for COVID-19(Trial Fifth Edition),both groups were treated with western medicine based antiviral and anti-infection treatment.The treatment group were additionally treated with Qingfei Touxie Fuzheng recipe.After 10 days of treatment,the clinical symptoms,physical examination indexes,and CT manifestations of both groups were collected for analysis and comparison. Results After 10 days of treatment,the treatment group was significantly better than the control group in alleviating clinical symptoms fever,coughing and expectoration,chest tightness and shortness of breath,promoting the absorption of pulmonary lesions,improving oxygenation,etc..Compared with the control group,the levels of ESR,CRP,and IL-6 were significantly decreased in the treatment group(P<0.05),and the difference was statistically significant. The level of IFN-γ was increased,but there was no statistical difference between the data analysis and comparison(P>0.05). Conclusion The treatment of COVID-19 with Qingfei Touxie Fuzheng recipe combined with western medicines was more effective than the treatment with western medicine alone,and the possible mechanism lies in the up-regulation of “antiviral” factors and down-regulation of “pro-inflammatory” factors.
ZHU N, ZHANG D Y,WANG W L,et al.A novel corona-virus from patients with pneumonia in China,2019[J].New Engl J Med,2020,382(5):727-733.
[2]
CHAN J F W,YUAN A F,KOK K H,et al.A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission:a study of a family cluster[J].Lancet,2020,395(10223):514-523.
YANG Y,LU Q,LIU M,et al.Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China[J/OL].[2020-02-21].Med Rxiv,
[5]
BARUAH V,BOSE S.Immunoinformatics-aided identifica-tion of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV[J].J Med Virol,2020,10.1002/jmv.25698.
MORSE J S, LALONDE T, XU S Q,et al.Learning from the past:possible urgent prevention and treatment options for severe acute respiratory infections caused by2019-nCoV[J/OL].[2020-01-27].Chembiochem,.
[9]
WANG M L, CAO R Y, ZHANG L K,et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV) in vitro[J/OL].[2020-02-04].Cell Res,.
[10]
HOLSHUE M L, DEBOLT C,LINDQUIST S,et al.First case of2019 novel coronavirus in the United States[J].[2020-01-31].New Engl J Med,.
[11]
LU H.Drug treatment options for the 2019-new coronavirus(2019-nCoV)[J].Biosci trends,2020,14(1):69-71.
MEI F,XING X F,TANG Q F,et al.Antipyretic andantias-thmatic activities of traditional Chinese herb-airs,ephedra and gypsum[J].Chin J Integr Med,2016,22(6):445-450.
YU S Y,HU Y W,LIU X Y,et al.Gene expression profiles in peripheral blood mononuclear cells of SARS patients[J].World J Gastroenterol,2005,11(32):5037-5043.
2020, Vol. 39 
),张勇1(
